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Abstract The cytoplasmic domain of the p80 TNF receptor 
associates with a protein kinase, termed p80TRAK, that 
phosphorylates both the p60 and p80 TNF receptors. To 
determine the region of the cytoplasmic domain that is necessary 
for binding of p80TRAK and the region that it phosphorylates, a 
series of deletions of the p80 cytoplasmic domain were 
constructed and expressed as glutathione-S-transferase fusion 
proteins. These fusions were then used to examine the binding of 
p80TRAK derived from cellular extracts. We found that out of 
174 residues (266-439) in the cytoplasmic domain of p80 
receptor, 44 residues (354-397) were sufficient for binding of 
p80TRAK. Interestingly, this was also the region that contained 
the phosphorylation site for p80TRAK. Phosphoamino acid 
analysis of this region revealed phosphorylation primarily on 
serine residues. Furthermore, we found that, like p80TRAK, 
purified casein kinase 1 (CK1) also binds to residues 354-397 of 
the p80 TNF receptor and causes its phosphorylation. Addition-
ally, the activity of p80TRAK was inhibited by CK1-7, the CK1-
specific inhibitor. Thus, our results indicate that p80TRAK 
associates with a short stretch of ~ 4 4 residues located in the 
cytoplasmic domain of the p80 TNF receptor and that this kinase 
is similar to CK1. 
© 1997 Federation of European Biochemical Societies. 
Key words: Tumor necrosis factor; Kinase; 
p80 TNF receptor; Phosphorylation 
1. Introduction 
Human tumor necrosis factor (TNF)1, a pleiotropic cyto-
kine, interacts with two distinct receptors designated p60 (p55, 
Type I) and p80 (p75, Type II) [1]. Although most of the early 
response elicited by TNF are transmitted through the 
p60 TNF receptor [2], direct signaling via the p80 receptor 
has been demonstrated on cells of lymphoid origin such as 
proliferation of the CT6 cell line [3-5] and induction of gran-
ulocyte/macrophage colony stimulatory factor by a T-cell hy-
bridoma [6]. Additionally, an independent signaling role for 
the p80 receptor has been demonstrated for TNF-mediated 
cytotoxicity in some specific cell lines [7-9] and for NF-kB 
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activation [5,10]. Although TNF induces the phosphorylation 
of various proteins [[1], references therein], the role of protein 
phosphorylation mediated by the TNF receptors remains un-
clear. Recent reports have indicated that the p80 receptor 
itself is constitutively phosphorylated in p80-responsive and 
nonresponsive cell lines [11,12]. In addition, a casein kin-
ase 1 -like activity (CK1) coprecipitates with the p80 receptor 
only in p80-responsive cell lines [11]. 
Results from our laboratory using a glutathione-S-transfer-
ase (GST) fusion protein containing the cytoplasmic domain 
of the p80 receptor indicated a serine/threonine kinase activity 
termed p80TRAK physically associated with the p80 cytoplas-
mic domain [13]. Unlike the p60 TNF receptor-associated kin-
ase (p60TRAK) [14], p80TRAK phosphorylated both the p60 
and p80 receptor [13]. The intracellular domain of the p80 
receptor contains 174 amino acids (residues 266^439), in which 
there are 43 potential phosphorylation sites (32 serine and 11 
threonine residues). In the present report, we sought to iden-
tify the minimal region of the cytoplasmic domain necessary 
for interaction with p80TRAK and also the region that under-
goes phosphorylation. In addition, we examined the relation-
ship of p80TRAK to a recombinant, purified form of CK1. 
2. Materials and methods 
2.1. Materials 
The histiocytic lymphoma cell line U-937 (CRL 1593) was obtained 
from the American Type Culture Collection (Rockville, MD) and 
maintained in a 5% CO2 atmosphere at 37°C in RPMI-1640 medium 
supplemented with 10% fetal bovine serum and penicillin-streptomy-
cin, all obtained from Life Technologies, Inc. (Grand Island, NY). 
Purified CK1 (4X 106 U/mg;) was purchased from New England Bio-
labs, Beverly, MA. The CKl-specific inhibitor CK1-7 was purchased 
from Seikagaku America Inc. (Rockville, MD). 
2.2. Construction, expression, and purification of GST fusion protein 
All subsequent DNA manipulations were carried out as described 
by Sambrook et al. [15]. Fig. 1 illustrates the fusion proteins that were 
made for this study. The 5'-primers 
CTAAGAGGATCCAAAAAGAAGCCCTTGTCCTG (WT,A1) 
CTAAGAGGATCCGGGACCCAGGTCAATGT- (A2, A5) 
CACC 
CTAAGAGGATCCCAGCACCTGCTGATCA- (A3, A4) 
CAGCG 
CTAAGAGGATCCACAATGGGAGACACA- (A6) 
GATTCC 
and the 3'-primers 
TCTTAGAAGCTTTTAACTTGGGCTTCATCC- (WT, A2, A6) 
CAGC 
TCTTAGAAGCTTTTAATGGCCACCAGGG- (Al, A4) 
GAAGA 
TCTTAGAAGCTTTTACTCGTCCTTCGGG- (A3, A5) 
GAACTC 
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were used to amplify fragments from pCMVXVBpL4-p80 with unique 
restriction sites PCR. The PCR products were digested with BamHIl 
Hindlll and inserted into digested pGEX-2TH to yield the appropri-
ate expression vector. Expression and purification of the GST fusion 
proteins from BL21 cells were carried out as previously described 
[14,16]. 
2.3. Binding of p80 TRAK to TNF receptor-GST fusion proteins 
For this U-937 cells (2 X 106) were lysed in 600 ul of lysis buffer (20 
mM HEPES, pH 7.4, 0.1% NP-40, 250 mM NaCl, 10 mM NaF, 1 mM 
PMSF, 2 ug/ml aprotinin, and 2 (ig/ml leupeptin) on ice for 30 min 
and then centrifuged for 10 min. The supernatant was diluted with 
lysis buffer without NaCl to yield a final concentration of 125 mM 
NaCl and precleared with 10 ug of GST bound to glutathione-agar-
ose beads for 1 h at 4°C. The precleared supernatant was mixed with 
approximately 5 u,g of GST or the appropriate fusion protein attached 
to glutathione-agarose beads for 1 h at 4°C. The beads were collected 
by centrifugation and washed extensively with the lysis buffer (4 X 500 
Hi) and with kinase buffer (2X500 ul: 20 mM HEPES, pH 7.4, 10 
mM NaF, and 0.1% 2-mercaptoethanol). 
2.4. In vitro kinase assays 
Standard kinase assays were carried out for 15 min at 37°C in 30 u.1 
containing 20 mM HEPES, pH 7.4, 10 mM MgCl2, 0.2 mM ATP, 0.2 
mM NaF, 0.1 mM sodium orthovanadate, and 10 uCi [y-32P]ATP. 
Reactions were stopped with 15 u.1 of SDS-sample buffer, boiled for 
5 min, and subjected to SDS-PAGE. Protein bands were visualized by 
staining with Coomassie Blue, and the dried gels were analyzed by a 
Phosphorimager (Molecular Dynamics, Sunnyvale, CA) and quanti-
tated by ImageQuant Software (Molecular Dynamics, Sunnyvale, 
CA). 
For in vitro binding and kinase assays with purified CK1 and the 
GST fusion proteins, we used a binding buffer that contained 20 mM 
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Fig. 1. Deletions of the cytoplasmic domain of the TNF receptor. A: Schematic of the cytoplasmic domain of the p80 TNF receptor (residues 
266-439) with the deletion constructs used in this study. All deletions were expressed as GST fusion proteins. B: An SDS-polyacrylamide gel 
stained with Coomassie Blue of the GST fusion proteins with the indicated molecular mass standards. 
TRIS, pH 7.6, 125 mM NaCl, 0.1% Triton X-100, 0.1% bovine serum 
albumin, 1 mM EDTA, and 1 mM EGTA. Approximately 5 ug of 
GST or the appropriate fusion protein attached to glutathione-agar-
ose beads was mixed with 10 U (2.5 ng) of purified CK1 in 600 u.1 of 
binding buffer for 1 h at 4°C. Proteins were collected by centrifuga-
tion and washed as described above (3X binding buffer and 2X 
kinase buffer). In vitro kinase assays were performed as above indi-
cated. 
3. Results 
We have previously reported that the cytoplasmic domain 
of the p80 TNF receptor physically associates with a serine/ 
threonine kinase termed p80TRAK [13]. To define the 
p80TRAK binding region in the cytoplasmic domain of the 
p80 receptor, we constructed a series of deletions of the cyto-
plasmic domain as illustrated in Fig. 1A. p80 wild-type (WT) 
contained the entire cytoplasmic domain of the p80 receptor 
(residues 266-349), and p80Al and p80A2 were the N- and C-
terminal halves of the cytoplasmic domain, respectively. Dele-
tion mutant p80A3 had truncations at both the N- and C-
terminus, and p80A4 and p80A5 were the N- and C-terminal 
halves of p80A3, respectively. The deletion mutant p80A6 en-
compassed the C-terminal 58 residues. All deletion mutants 
were made as GST fusion proteins, expressed in Escherichia 
coli, and purified by affinity chromatography on glutathione-
agarose beads [14]. A Coomassie Blue-stained gel of the fusion 
proteins used in this study appears in Fig. IB. 
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Fig. 2. p80TRAK binds to and phosphorylates a minimal region of 44 residues within the p80 cytoplasmic domain. A: U937 cell lysates from 
2X 106 per assay were prepared, and affinity precipitations were performed with the indicated GST fusion protein. In vitro kinase assays were 
performed as described under Section 2. The samples were analyzed by 9% SDS-PAGE, and the dried gel exposed to X-ray film for 3 h at 
-70°C. Relative mobilities for the various fusion proteins were identified by Coomassie Blue staining. B: Phosphoamino acid analysis of p80WT 
and p80A5 was performed as previously described [17]. The positions of phosphoserine, -threonine, and -tyrosine was indicated by staining the 
TLC plate with ninhydrin. 
3.1. p80TRAK binds to a minimal region of 44 residues of the 
p80 cytoplasmic domain 
To ascertain which region of the cytoplasmic domain asso-
ciates with p80TRAK, the GST fusion proteins were used to 
affinity precipitate p80TRAK from U937 cell lysates followed 
by in vitro kinase assays. p80TRAK activity bound to and 
phosphorylated p80WT (100%), p80A2 (103%), p80A3 (49%), 
p80A5 (52%), and p80A6 (30%), but not GST (6%), p80Al 
(14%), and p80A4 (6%) (Fig. 2A). The variable phosphoryla-
tion was not due to lack of potential phosphorylation sites 
because when myelin basic protein was used as an exogenous 
substrate, the phosphorylation by the kinase which associates 
with p80WT, p80Al, p80A2, p80A3, p80A4, p80A5, p80A6 and 
GST remained unchanged (i.e., 100%, 36%, 72%, 49%, 32%, 
78%, 34% and32%>, respectively). The phosphorylation pat-
terns of p80WT, p80Al, and p80A2 considered together imply 
that the C-terminal half (p80A2), but not the membrane prox-
imal half (p80Al) of the p80 cytoplasmic domain is necessary 
for p80TRAK binding. Within the C-terminal half, a small 
region of 44 residues (p80A5, residues 354-397) was sufficient 
for binding p80TRAK (Fig. 2A). 
Phosphoamino acid analysis of p80WT and p80A5 indi-
cated predominantly serine phosphorylation (85% and 91%>, 
respectively) with a small amount of threonine phosphoryla-
tion and (14%o and 9%>, respectively) (Fig. 2B). There was no 
incorporation on tyrosine in either case, since the cytoplasmic 
domain of the p80 receptor does not contain any tyrosine 
residues. Thus, the minimal region of the cytoplasmic domain 
of the p80 receptor that interacts with p80TRAK is contained 
in the C-terminus, residues 354-397 (p80A5). 
3.2. Purified CK1 also associates with residues 354-397 
(p80h5) in vitro 
Previously, it has been shown that CK-1 coprecipitates with 
the p80 TNF receptor from PC60 cells transfected with both 
TNF receptors [11]. Since p80A5 is sufficient for binding and 
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Fig. 3. Purified CKl binds to and phosphorylates the p80 cytoplas-
mic domain. An in vitro kinase assay with 2.5 U of purified CKl 
(A) or an in vitro binding and kinase assay with 10 U of purified 
CKl (B) with the indicated fusion proteins was performed as de-
scribed under Section 2. Reaction mixtures were analyzed by 9% 
SDS-PAGE, and the dried gel exposed to a Phosphorlmager screen. 
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phosphorylation by p80TRAK and this deletion contains po-
tential CKl phosphorylation sites, we tested all the p80 dele-
tion mutants to identify which region could potentially serve 
as substrate for purified CKl. Purified CKl phosphorylated 
p80WT (100%), p80A2 (217%), p80A3 (152%), p80A5 (149%), 
and to a lesser extent p80A6 (75%), but not GST (7%), p80Al 
(7%), and p80A4 (3%) (Fig. 3A). The phosphorylation was 
dose- and time-dependent (data not shown). Differences in 
the amount of phosphorylation of the GST fusion proteins 
by CKl may reflect the number of different phosphorylation 
sites remaining in the deletion mutant. The phosphorylation 
pattern of the p80 deletion mutants observed for CKl (Fig. 
3A) was similar to that for p80TRAK precipitated from U937 
cell extracts (Fig. 2A). 
Since CKl could phosphorylate specific regions of the p80 
cytoplasmic domain, we next determined whether CKl could 
bind to the p80 cytoplasmic domain. We first incubated puri-
fied CKl with each of the GST fusion proteins for 1 h at 4°C, 
washed the mixtures extensively with binding buffer, and then 
performed an in vitro kinase assay (Fig. 3B). The results with 
purified CKl (Fig. 3B) were indistinguishable from those ob-
tained with p80TRAK from U937 cells (Fig. 2A). The phos-
phorylated band migrating at approximately 33 kDa may re-
flect autophosphorylation of the purified CKl in the presence 
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Fig. 4. A CKl-specific inhibitor blocks p80TRAK activity. An in vitro kinase assay with 10 U of purified CKl (A) or p80TRAK precipitated 
from U937 cells with p80A5 (B) using p80A5 as a substrate was performed in the presence of the indicated concentration of CKl-7 dissolved in 
DMSO. The asterisk represents a control in which DMSO was added to a final concentration of 1.6%. Reaction mixtures were analyzed by 9% 
SDS-PAGE, and the dried gel was exposed to a Phosphorlmager sreen. The phosphorylation of p80A5 was quantitated by ImageQuant Soft-
ware (Molecular Dynamics, Sunnyvale, CA). 
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of bovine serum albumin in the binding assay2. Thus, it ap-
pears that p80TRAK which binds the cytoplasmic domain of 
the p80 receptor is closely related to CK1. 
3.3. p80TRAK activity is inhibited by CKl-7, a CKl-specific 
inhibitor 
To further support that p80TRAK activity is similar to 
CK1 activity, we compared the kinase activity of purified 
CK1 and p80TRAK with increasing concentrations of CK1-
7, a specific inhibitor of CK1. As measured by phosphoryla-
tion of p80A5, CKl-7 inhibited the phosphorylation of the 
receptor by both CK1 and p80TRAK in a dose-dependent 
manner. A concentration of 100 |xM CKl-7 was needed to 
inhibit by 80% and 50% of CK1 and p80TRAK, respectively 
(Fig. 4). 
4. Discussion 
This report provides evidence that a minimal region of 44 
residues (p80A5, 354-397) residing near the C-terminus of the 
p80 cytoplasmic domain is necessary for binding of p80TRAK 
and also undergoes serine phosphorylation by p80TRAK. We 
further demonstrated using CK1, that CKl's binding site and 
its phosphorylation of the p80 cytoplasmic domain is indis-
tinguishable from that of p80TRAK. Additionally, p80TRAK 
could be partially inhibited by a CKl-specific kinase inhibitor, 
suggesting that p80TRAK is similar to CK1. 
The p80 cytoplasmic domain contains 43 potential residues 
for phosphorylation. While there are nine potential phosphor-
ylation sites for CK1 within the N-terminus of the p80 cyto-
plasmic domain, p80Al (residues 266-353) was not phos-
phorylated by CK1 nor p80TRAK. However, the minimal 
region (p80A5; residues 354-397) of the p80 cytoplasmic do-
main that was serine phosphorylated by p80TRAK contains 
13 serines and 4 threonine residues. Within this region, a CK1 
consensus site of the sequence Ser(P)-Xaa-Xaa-Ser/Thr [18] 
is repeated 4 times. The putative binding site of p80TRAK is 
also located within a region of the p80 cytoplasmic domain 
that is necessary for binding TRAF2 [5]. The constitutive 
presence of the phosphorylated form of the p80 TNF receptor 
[11,12] and its association with TRAF2 [5] may suggest that 
the phosphorylated form of the receptor binds to TRAF2. 
Whether phosphorylation of the p80 TNF receptor is critical 
for the recruitment of TRAF2 is not known. Interestingly, 
blocking the phosphorylation of the p80 receptor by a CK1 
inhibitor, potentiated TNF-induced apoptosis mediated by the 
p80 receptor [11], suggesting an inhibitory role for phosphor-
ylation of the receptor by CK1. 
In summary, our data demonstrate that a small region of 
105 
approximately 44 residues of the p80 cytoplasmic domain is 
sufficient for binding p80TRAK and purified, recombinant 
CK1. The observations that the p80 TNF receptor is phos-
phorylated in vivo and that p80TRAK binds within a region 
also necessary for TRAF2 interaction suggests that phosphor-
ylation may play a role in TRAF2 association. Besides the 
receptor, TRAF2 itself contains potential phosphorylation 
sites for p80TRAK. It is possible that p80TRAK described 
here phosphorylates not only the receptor, but also TRAF2 
and other related proteins that mediated signal transduction 
via the p80 TNF receptor. 
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